Document:

Exhibit 4.4

 

Warrant No. [ ]

 

THIS WARRANT AND THE SECURITIES
ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES
LAWS, AND, ACCORDINGLY, MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED UNLESS (I) SUCH SECURITIES HAVE
BEEN REGISTERED FOR SALE PURSUANT TO THE SECURITIES ACT OF 1933, AS AMENDED, OR (II) THE COMPANY HAS RECEIVED (IF REQUESTED BY THE COMPANY)_AN
OPINION OF COUNSEL REASONABLY SATISFACTORY TO IT THAT SUCH TRANSFER MAY LAWFULLY BE MADE WITHOUT REGISTRATION UNDER THE SECURITIES ACT
OF 1933, AS AMENDED.

 

Date of Issuance: [ ], 2015
(“Issuance Date”)

 

VARIANT PHARMACEUTICALS, INC.

WARRANT CERTIFICATE

 

FOR VALUE RECEIVED, Variant
Pharmaceuticals, Inc., a Florida corporation (the “Company”), hereby certifies that L&F Research LLC,
or its registered transferees, successors or assigns (each Person (as defined below) holding all or a part of this Warrant being referred
to as a “Holder”), is the registered holder of this Warrant (the “Warrant”) to subscribe for the
purchase of [ ] Warrant Shares (as defined below), as adjusted from time to time as provided herein, during the Exercise Period (as defined
below), all subject to the following terms and conditions.

 

This Warrant (the “Warrant”)
is being issued pursuant to the Subscription Agreement, dated as of the date hereof (the “Subscription Agreement”),
by and between the Company and L&F Research LLC, which was entered into in connection with the License Agreement, effective as of
the Issuance Date set forth above, by and between the Company and L&F Research LLC (the “License Agreement”).

 

For purposes of this Warrant
the following terms shall have the following meanings:

 

“Business Day”
means any day other than Saturday, Sunday or other day on which commercial banks in The City of Miami are authorized or required by law
to remain closed.

 

“Change in Control”
shall be deemed to have occurred if (i) there shall be consummated (A) any consolidation, merger or other business combination of the
Company in which the Company is not the continuing or surviving corporation or pursuant to which shares of the Company’s Common
Stock would be converted into cash, securities or other property, other than a consolidation, merger or other business combination of
the Company in which the holders of the Company’s Common Stock immediately prior to the merger have substantially the same proportionate
ownership of common stock of the surviving corporation immediately after the merger, or (B) any sale, lease, exchange or other transfer
(in one transaction or a series of related transactions) of all or substantially all the assets of the Company, or (ii) the stockholders
of the Company shall approve any plan or proposal for the liquidation or dissolution of the Company, or (iii) any Person (as such term
is used in Sections 13(d) and 14(d)(2) of the Securities Exchange Act of 1934 (the “Exchange Act”)), other than the
Company or any executive benefit plan sponsored by the Company, or such Person who on the date hereof is a 20% or more beneficial owner,
shall become the beneficial owner (within the meaning of Rule 13d-3 under the Exchange Act) of securities of the Company representing
50% or more of the combined voting power of the Company’s then outstanding securities ordinarily (and apart from rights accruing
in special circumstances) having the right to vote in the election of directors, as a result of a tender or exchange offer, open market
purchases, privately negotiated purchases or otherwise, or (iv) at any time during a period of two consecutive years, individuals who
at the beginning of such period, constituted the Board of Directors of the Company shall cease for any reason to constitute at least a
majority thereof, unless the election or the nomination for election by the Company’s stockholders of each new director during such
two-year period was approved by a vote of at least two-thirds of the directors then still in office, who were directors at the beginning
of such two-year period.

 

    

     

    

 

“Common Stock”
means the Common Stock, par value $0.00001 per share, of the Company.

 

“Exercise Date”
means the earlier of (i) [the date hereof] OR [the date on which [specify the applicable milestone set forth in Exhibit
B of the Subscription Agmt] has been satisfied] and (ii) the date that is twenty (20) Business Days before the earlier of (A) the effective
date of the first Change in Control after the date hereof and (B) the record date, if any, with respect such Change in Control.

 

“Exercise Price”
means [$1.00 per share] OR [the price per share of Common Stock that the Company sells to the first bona fide, third party
investor after the date hereof.]

 

“Expiration Date”
means the earlier of (i) 11:59 p.m., Miami Time, on the fifth anniversary of the Exercise Date and (ii) the date and time that the first
Change in Control is consummated.

 

“Person” means
an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization, any
other entity or a government or any department or agency thereof.

 

”Warrant Shares”
shall mean shares of Common Stock issuable upon exercise of the Warrant.

 

1. DURATION
AND EXERCISE OF WARRANTS

 

(a) Exercise
Period. The Holder may exercise this Warrant in whole or in part at any time from and after the Exercise Date and on or before the
Expiration Date (the “Exercise Period”).

 

(b) Exercise
Procedures.

 

(i) While
this Warrant remains outstanding and exercisable in accordance with Section 1(a), the Holder may exercise this Warrant in whole or in
part at any time and from time to time by:

 

(A) delivery
to the Secretary of the Company of a duly executed copy of the Notice of Exercise attached as Exhibit A;

 

(B) surrender
of this Warrant to the Secretary of the Company at its principal offices or at such other office or agency as the Company may specify
in writing to the Holder; and

 

(C) payment
of the then-applicable Exercise Price per share multiplied by the number of Warrant Shares being purchased upon exercise of the Warrant
(such amount, as calculated at the time of each exercise, the “Aggregate Exercise Price”) made in the form of cash,
or by certified check, bank draft or money order payable in lawful money of the United States of America.

 

In lieu of delivering the Exercise
Price in cash or check, bank draft or money order, the Holder may elect to exercise this Warrant by surrendering a portion of the Warrant
Shares to satisfy the aggregate Exercise Price (“Net Issue Exercise”). If the Holder wishes to elect the Net Issue
Exercise, the Holder shall notify the Company of its election in writing at the time it delivers to the Company the Notice of Exercise.
In the event the Holder shall elect Net Issue Exercise, the Holder shall receive the number of shares of Common Stock equal to the product
of (a) the number of shares of Common Stock purchasable under the Warrant, or portion thereof being exercised, and (b) the Current Market
Value (defined below) of one share of Common Stock minus the Exercise Price, divided by (c) the Current Market Value of one share of Common
Stock. Current Market Value means: (1)If the Common Stock is listed on a national securities exchange or admitted to unlisted trading
privileges on such exchange or listed for trading on the NASDAQ system, the Current Market Value shall be the last reported sale price
of the Common Stock on such exchange or system on the last Business Day prior to the date of exercise of this Warrant, or if no such sale
is made on such day, the average closing bid and asked prices for such day on such exchange or system; (2) If the Common Stock is not
so listed or admitted to unlisted trading privileges, the Current Market Value shall be the mean of the last reported bid and asked prices
reported by the National Quotation Bureau, Inc. on the last Business Day prior to the date of the exercise of this Warrant; or (3) If
the Common Stock is not so listed or admitted to unlisted trading privileges and bid and asked prices are not so reported, the Current
Market Value shall be determined in good faith by the Company’s Board of Directors.

 

    2

     

    

 

(ii) Upon
the exercise of this Warrant in compliance with the provisions of this Section 1(b), the Company shall promptly issue and cause to be
delivered to the Holder a certificate for the Warrant Shares purchased by the Holder. Each exercise of this Warrant shall be effective
immediately prior to the close of business on the date (the “Date of Exercise”) that the conditions set forth in Section
1(b) have been satisfied. On the first Business Day following the date on which the Company has received each of the Notice of Exercise
and the Aggregate Exercise Price (the “Exercise Delivery Documents”), the Company shall transmit an acknowledgment
of receipt of the Exercise Delivery Documents to the Company’s transfer agent, if other than the Company (the “Transfer
Agent”). On or before the third Business Day following the date on which the Company has received all of the Exercise Delivery
Documents (the “Share Delivery Date”), the Company at its expense shall (X) provided that the Transfer Agent is participating
in The Depository Trust Company (“DTC”) Fast Automated Securities Transfer Program, upon the request of the Holder,
credit such aggregate number of shares of Common Stock to which the Holder is entitled pursuant to such exercise to the Holder’s
or its designee’s balance account with DTC through its Deposit Withdrawal Agent Commission system, or (Y) if the Transfer Agent
is not participating in the DTC Fast Automated Securities Transfer Program or if the Warrant Shares are not eligible for inclusion therein
or if the Holder shall so request, issue and dispatch by overnight courier to the address as specified in the Notice of Exercise, a certificate,
registered in the Company’s share register in the name of the Holder or its designee, for the number of Warrant Shares to which
the Holder is entitled pursuant to such exercise. Upon delivery of the Exercise Delivery Documents, the Holder shall be deemed for all
corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective
of the date of delivery of the certificates evidencing such Warrant Shares.

 

(c) Partial
Exercise. This Warrant shall be exercisable, either in its entirety or from time to time in part, only for the number of Warrant Shares
available for exercise under this Warrant. If this Warrant is exercised and the number of Warrant Shares represented by this Warrant submitted
for exercise is greater than the actual number of Warrant Shares being acquired upon such an exercise, then the Company shall, as soon
as practicable and in no event later than five (5) Business Days after any such exercise and at its own expense, issue a new Warrant of
like tenor representing the right to purchase the remaining number of Warrant Shares purchasable hereunder after such exercise.

 

(d) Disputes.
In the case of a dispute as to the determination of the Exercise Price or the arithmetic calculation of the Warrant Shares, the Company
shall promptly issue to the Holder the number of Warrant Shares that are not disputed and resolve such dispute in accordance with the
Subscription Agreement.

 

(e) Company’s
Failure to Timely Deliver Securities.  Upon the exercise of this Warrant in compliance with the provisions of this Section 1,
if the Company shall fail for any reason or for no reason to issue to the Holder by the Share Delivery Date, in accordance with Section
1(b) hereof, the Warrant Shares to which the Holder is entitled upon the Holder’s exercise (or deemed exercise) of this Warrant, and if
on or after such Share Delivery Date the Holder purchases (in an open market transaction or otherwise) shares of Common Stock to deliver
in satisfaction of a sale by the Holder of shares of Common Stock issuable upon such exercise that the Holder anticipated receiving from
the Company (a “Buy-In”), then the Company shall, within three (3) Business Days after the Holder’s request and
in the Holder’s discretion, either: (i) pay cash to the Holder in an amount equal to the Holder’s total purchase price (including
brokerage commissions and other accountable, out of pocket expenses, if any) for the shares of Common Stock so purchased (the “Buy-In
Price”), at which point the Company’s obligation to issue such shares of Common Stock shall terminate; or (ii) promptly
honor its obligation to deliver the Warrant Shares, in accordance with Section 1(b) hereof, and pay cash to the Holder in an amount equal
to the excess (if any) of the Buy-In Price over the product of (A) the number of Warrant Shares, times (B) the closing sale
price (or value of a single share of Common Stock, if otherwise derived) on the date of exercise.  Nothing shall limit the Holder’s
right to pursue any other remedies available to it hereunder, at law or in equity, including, without limitation, a decree of specific
performance and/or injunctive relief with respect to the Company’s failure to timely deliver the Warrant Shares upon the exercise (or
deemed exercise) of this Warrant as required pursuant to the terms hereof.

 

    3

     

    

 

2. ISSUANCE
OF WARRANT SHARES

 

(a) The
Company covenants that all Warrant Shares will, upon issuance in accordance with the terms of this Warrant, be (i) duly authorized, fully
paid and non-assessable, and (ii) free from all liens, charges and security interests, with the exception of claims arising through the
acts or omissions of any Holder and except as arising from applicable Federal and state securities laws.

 

(b) The
Company shall register this Warrant upon records to be maintained by the Company for that purpose in the name of the record holder of
such Warrant from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner thereof for
the purpose of any exercise thereof, any distribution to the Holder thereof and for all other purposes.

 

(c) The
Company will not, by amendment of its certificate of incorporation, by-laws or through any reorganization, transfer of assets, consolidation,
merger, dissolution, issuance or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance
of any of the terms to be observed or performed hereunder by the Company, and will take all actions consistent with the carrying out of
all the provisions of this Warrant.

 

3. ADJUSTMENTS OF EXERCISE
PRICE, NUMBER AND TYPE OF WARRANT SHARES

 

(a) The
Exercise Price and the Warrant Shares issuable upon the exercise of this Warrant shall be subject to adjustment from time to time upon
the occurrence of certain events described in this Section 3.

 

(i) Subdivision
or Combination of Stock. In case the Company shall at any time after the date hereof and prior to the Expiration Date subdivide (whether
by way of stock dividend (other than as a result of an event provided for in Section 3(a)(ii) below), stock split or otherwise) its outstanding
Common Stock into a greater number of shares, the Exercise Price in effect immediately prior to such subdivision shall be proportionately
reduced and the number of Warrant Shares shall be proportionately increased, and conversely, in case the outstanding Common Stock shall
be combined (whether by way of stock combination, reverse stock split or otherwise) into a smaller number of shares, the Exercise Price
in effect immediately prior to such combination shall be proportionately increased and the number of Warrant Shares issuable upon the
exercise of this Warrant shall be proportionately decreased. The Exercise Price and the Warrant Shares issuable upon the exercise of this
Warrant, as so adjusted, shall be readjusted in the same manner upon the happening of any successive event or events described in this
Section 3(a)(i).

 

(ii) Dividends
in Stock, Property, Reclassification. If at any time, or from time to time, after the date hereof and prior to the Expiration Date,
(x) there are changes in the outstanding Common Stock by reason of recapitalization, reclassification or reorganization of the capital
stock of the Company (other than as a result of any event provided for in Section 3(a)(i) above), or (y) all of the holders of Common
Stock shall have received or become entitled to receive, without payment therefor (other than as a result of any event provided for in
Section 3(a)(i) above):

 

(A) any
shares of stock or other securities that are at any time directly or indirectly convertible into or exchangeable for Common Stock, or
any rights or options to subscribe for, purchase or otherwise acquire any of the foregoing by way of dividend or other distribution, or

 

(B) additional
stock or other securities or property (including cash) by way of spin-off, split-up, reclassification, combination of shares or similar
corporate rearrangement,

 

then, and in each such case,
the Exercise Price and the number of Warrant Shares issuable upon exercise of this Warrant shall be adjusted proportionately, and the
Holder hereof shall, upon the exercise of this Warrant, be entitled to receive, in addition to the number of shares of Warrant Shares
receivable upon exercise of this Warrant, and without payment of any additional consideration therefor, the amount of stock and other
securities and property (including cash in the cases referred to above) that such Holder would hold on the date of such exercise had such
Holder been the holder of record of such Warrant Shares as of the date on which such holders of Common Stock received or became entitled
to receive such shares or all other additional stock and other securities and property (without regard to any limitations on exercise
hereof, including, without limitation, those, if any, making this Warrant not yet exercisable as of such date). The Exercise Price and
the Warrant Shares issuable upon the exercise of this Warrant, as so adjusted, shall be readjusted in the same manner upon the happening
of any successive event or events described in this Section 3(a)(ii).

 

    4

     

    

 

(b) Certificate
as to Adjustments. Upon the occurrence of each adjustment or readjustment pursuant to this Section 3, the Company at its expense shall
promptly compute such adjustment or readjustment in accordance with the terms hereof and furnish to each Holder of this Warrant a certificate
setting forth such adjustment or readjustment and showing in detail the facts upon which such adjustment or readjustment is based.

 

4. CHANGE
IN CONTROL.

 

(a) Upon
the consummation of a Change in Control, this Warrant shall automatically terminate. Prior to the consummation of a Change in Control,
the Company shall make appropriate provision, including providing the notice set forth in Section 17 hereof, so that the Holder shall
have the right to receive, with respect to the Holder’s Warrant Shares, upon exercise of the Warrant, the same consideration that
the holders of the Common Stock shall receive in connection with the consummation of the Change in Control.

 

(b) Notwithstanding
anything in Section 4(a) above to the contrary, this Warrant shall be deemed to have been exercised in accordance with Section 1, without
any action on the part of the Holder, immediately prior to any Change in Control, if the consideration to be paid with respect to each
share of Common Stock in such Change in Control is greater than the Exercise Price; provided, however, that the deemed exercise
as per this Section 4(b) shall not occur if Holder in its sole discretion elects in writing, by notice to the Company not later than the
fifth day preceding the consummation of such Change in Control, not to have such deemed exercise occur.

 

5. REGISTRATION
RIGHTS

 

(a) Except in connection with
the initial public offering of the Company’s Common Stock or other equity securities (the “IPO”), for which the
Holder shall not have any registration rights hereunder, whenever the Company proposes to register any of its equity securities under
the Securities Act, excluding registrations on Forms S-4 or S-8, and the registration form to be used may be used for the registration
of shares of Common Stock, whether a sale for the Company’s own account or for selling security holders (a “Piggyback Registration”),
the Company will give written notice to the Holder prior to the filing of the registration statement of the Company’s intention
to effect such a registration and, subject to the sentence immediately following and the Holder’s compliance with the requirements
set forth in this Section 5, will include in such registration all Warrant Shares with respect to which the Company has received written
request for inclusion therein within twenty (20) Business Days after the sending of the foregoing Company notice. If a Piggyback Registration
is an underwritten registration, and the managing underwriters advise the Company that, in their opinion, the number of securities requested
to be included in such registration exceeds the number which can be sold in such offering without adversely affecting the marketability,
proposed offering price, timing, distribution method or probability of success of such offering (an “Adverse Effect”),
then the Company will include in such registration: (i) first, all of the securities that the Company proposes to sell; (ii) second, all
of the securities the Company is required to register under agreements entered into in 2015 (or earlier) that have priority registration
rights; and (iii) third, the Warrant Shares requested to be included by the Holder and other holders of the Warrant Shares and other securities
held by stockholders that have registration rights and have requested inclusion in such registration, which in the opinion of such underwriters
can be sold without an Adverse Effect on the offering, pro rata among such holders on the basis of the number of such securities owned
by each such holder. To facilitate the allocation of shares in accordance with the above provisions, the underwriters may round the number
of shares allocated to any holder to the nearest 100 shares. All underwriting, legal, accounting, marketing and other registration expenses
of the Piggyback Registration will be borne entirely by the Company. Nothing herein shall prohibit the Company from granting registration
rights in the future to security holders of the Company that rank pari pasu with the rights of the Holder.

 

(b) Notwithstanding anything
in Section 5(a) hereof to the contrary, the Holder shall not have any registration rights hereunder unless it (i) agrees to sell its Warrant
Shares on the basis provided in any underwriting arrangements approved by the Company and other Persons registering securities in the
Piggyback Registration, and (ii) completes and executes all questionnaires, powers of attorney, indemnities, underwriting agreements and
other documents reasonably required under the terms of such underwriting arrangements or reasonably requested by the Company.

 

    5

     

    

 

(c) If the Company proposes to
or expects that at any time it will or may consummate an offering pursuant to which the Holder has registration rights under Section 5(a)
hereof, then, in connection therewith, the Company shall give Holder written notice at least twenty (20) Business Days prior to the anticipated
effective date of the registration statement.

 

6. TRANSFERS
AND EXCHANGES OF WARRANT AND WARRANT SHARES

 

(a) Registration
of Transfers and Exchanges. Subject to Section 6(c), 6(d) and 6(e) hereof, upon the Holder’s surrender of this Warrant, with
a duly executed copy of the Form of Assignment attached as Exhibit B, to the Secretary of the Company at its principal offices
or at such other office or agency as the Company may specify in writing to the Holder, the Company shall register in the Company’s
books and records the transfer of all or any portion of this Warrant. Upon such registration of transfer, the Company shall issue a new
Warrant, in substantially the form of this Warrant, evidencing the acquisition rights transferred to the transferee and a new Warrant,
in similar form and dated as of the Issuance Date, evidencing the remaining acquisition rights not transferred, to the Holder requesting
the transfer.

 

(b) Warrant
Exchangeable for Different Denominations. The Holder may exchange this Warrant for a new Warrant or Warrants, in substantially the
form of this Warrant, evidencing in the aggregate the right to purchase the number of Warrant Shares which may then be purchased hereunder,
each of such new Warrants to be dated the Issuance Date and to represent the right to purchase such number of Warrant Shares as shall
be designated by the Holder. The Holder shall surrender this Warrant with duly executed instructions regarding such re-certification of
this Warrant to the Secretary of the Company at its principal offices or at such other office or agency as the Company may specify in
writing to the Holder.

 

(c) Restrictions
on Transfers. This Warrant may not be transferred at any time unless such transfer is (i) registered under the Securities Act or (ii)
the Company has received (if requested by the Company) an opinion of legal counsel reasonably satisfactory to the Company that the proposed
transfer of the Warrant may be lawfully effected without registration under the Securities Act.

 

(d) Permitted
Transfers and Assignments. Notwithstanding any provision to the contrary in this Section 6, the Holder may transfer, with or without
consideration, this Warrant or any of the Warrant Shares (or a portion thereof) to the Holder’s Affiliates (as such term is defined
under Rule 144 of the Securities Act) without obtaining the opinion from counsel that may be required by Section 6(c)(ii), provided,
that the Holder delivers to the Company and its counsel certification, documentation, and other assurances reasonably required by
the Company’s counsel to enable the Company’s counsel to render an opinion to the Company’s Transfer Agent that such
transfer does not violate applicable securities laws.

 

(e) Lockup.
No transfer of this Warrant shall be effected unless the transferee agrees, in writing, to be subject to the lockup terms set forth in
Section 8 of the Subscription Agreement.

 

7. MUTILATED
OR MISSING WARRANT CERTIFICATE

 

If this Warrant is mutilated,
lost, stolen or destroyed, upon request by the Holder, the Company will, at the Company’s expense, issue, in exchange for and upon
cancellation of the mutilated Warrant, or in substitution for the lost, stolen or destroyed Warrant, a new Warrant, dated as of the Issuance
Date and in substantially the form of this Warrant, representing the right to acquire the equivalent number of Warrant Shares; provided,
that, the Holder provides the Company with an affidavit of loss and an indemnity agreement reasonably satisfactory to the Company.

 

8. PAYMENT
OF TAXES

 

The Company will pay all transfer
and stock issuance taxes attributable to the preparation, issuance and delivery of this Warrant and the Warrant Shares (and replacement
Warrants) including, without limitation, all documentary and stamp taxes; provided, however, that the Company shall not be required
to pay any tax in respect of the transfer of this Warrant, or the issuance or delivery of certificates for Warrant Shares or other securities
in respect of the Warrant Shares to any Person or entity other than to the Holder.

 

    6

     

    

 

9. FRACTIONAL
WARRANT SHARES

 

No fractional Warrant Shares
shall be issued upon exercise of this Warrant. The Company, in lieu of issuing any fractional Warrant Share, shall round up the number
of Warrant Shares issuable to nearest whole share.

 

10. NO
STOCK RIGHTS AND LEGEND

 

No holder of this Warrant, as
such, shall be entitled to vote or be deemed the holder of the Warrant Shares or any other securities of the Company that may at any time
be issuable on the exercise hereof, nor shall anything contained herein be construed to confer upon the holder of this Warrant, as such,
the rights of a stockholder of the Company or the right to vote for the election of directors or upon any matter submitted to stockholders
at any meeting thereof, or give or withhold consent to any corporate action or to receive notice of meetings or other actions affecting
stockholders (except as provided herein), or to receive dividends or subscription rights or otherwise (except as provided herein).

 

Each certificate for Warrant
Shares initially issued upon the exercise of this Warrant, and each certificate for Warrant Shares issued to any subsequent transferee
of any such certificate, shall be stamped or otherwise imprinted with a legend in substantially the following form:

 

“THE SECURITIES REPRESENTED
HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS, AND, ACCORDINGLY, MAY NOT
BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT
TO THE SECURITIES ACT OF 1933, AS AMENDED, OR (II) THE COMPANY HAS RECEIVED (IF REQUESTED BY THE COMPANY) AN OPINION OF COUNSEL REASONABLY
SATISFACTORY TO IT THAT SUCH TRANSFER MAY LAWFULLY BE MADE WITHOUT REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED.”

 

11. CERTAIN
INFORMATION

 

At all times prior to the Company’s IPO,
the Company agrees to provide, subject to any legal or contractual restrictions applicable to the Company, Holder at any time and from
time to time with such information as Holder may reasonably request for purposes of Holder’s compliance with regulatory, accounting and
reporting requirements applicable to Holder.

 

12. NOTICES

 

Any notice or other communication
required or permitted to be given hereunder shall be in writing and shall be deemed effectively given: (a) upon personal delivery to the
party notified, (b) when sent by confirmed email or facsimile if sent during normal business hours of the recipient, if not, then on the
next Business Day, (c) five days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or
(d) one day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt.
All communications shall be sent to the Company at the address, email or facsimile number provided in the License Agreement executed in
connection herewith, and to the Holder at the address, email or facsimile number provided in the License Agreement for such Holder executed
in connection herewith, or to such other address as the Company or the Holder shall have furnished in writing in accordance with the provisions
of this Section 12.

 

13. SEVERABILITY

 

If a court of competent jurisdiction
holds any provision of this Warrant invalid or unenforceable, the other provisions of this Warrant will remain in full force and effect.
Any provision of this Warrant held invalid or unenforceable only in part or degree will remain in full force and effect to the extent
not held invalid or unenforceable.

 

    7

     

    

 

14. BINDING
EFFECT

 

This Warrant shall be binding
upon and inure to the sole and exclusive benefit of the Company, its successors and assigns, the registered Holder or Holders from time
to time of this Warrant and the Warrant Shares.

 

15. REMEDIES,
CHARACTERIZATION, OTHER OBLIGATIONS, BREACHES AND INJUNCTIVE RELIEF.

 

The remedies provided in this
Warrant shall be cumulative and in addition to all other remedies available under this Warrant, at law or in equity (including a decree
of specific performance and/or other injunctive relief), and nothing herein shall limit the right of the Holder to pursue actual damages
for any failure by the Company to comply with the terms of this Warrant. The Company covenants to the Holder that there shall be no characterization
concerning this instrument other than as expressly provided herein. The Company acknowledges that a breach by it of its obligations hereunder
will cause irreparable harm to the Holder and that the remedy at law for any such breach may be inadequate. The Company therefore agrees
that, in the event of any such breach or threatened breach, the holder of this Warrant shall be entitled, in addition to all other available
remedies, to an injunction restraining any breach, without the necessity of showing economic loss and without any bond or other security
being required. The Company shall provide all information and documentation to the Holder that is reasonably requested by the Holder to
enable the Holder to confirm the Company’s compliance with the terms and conditions of this Warrant (including, without limitation, compliance
with Section 3 hereof).

 

16. SURVIVAL
OF RIGHTS AND DUTIES

 

This Warrant shall terminate
and be of no further force and effect on the earlier of the expiration of the Exercise Period or the date on which this Warrant has been
exercised in full.

 

17. NOTICES
OF RECORD DATE AND OTHER MATTERS

 

In connection with (a) any establishment
by the Company of a record date of the holders of any class of securities for the purpose of determining the holders thereof who are entitled
to receive any dividend or other distribution, or right or option to acquire securities of the Company, or any other right, or (b) any
contemplated capital reorganization, reclassification, recapitalization, merger or consolidation of the Company with or into any other
corporation, any transfer of all or substantially all the assets of the Company, or any voluntary or involuntary dissolution, liquidation
or winding up of the Company, or the sale, in a single transaction or series of transactions, of a majority of the Company’s voting
stock (whether newly issued, or from treasury, or previously issued and then outstanding, or any combination thereof), or (c) any anticipated
Change in Control not described in preceding clause(s) (a) and/or (b), the Company shall give notice to the Holder at least twenty (20)
Business Days, or such longer period as may be required by law, prior to such event, a notice specifying (i) the date expected to be established
as the record date for the purpose of such dividend, distribution, option or right and a description of such dividend, option or right,
(ii) the date on which any such reorganization, reclassification, transfer, consolidation, merger, dissolution, liquidation or winding
up, sale or other Change in Control is expected to become effective and (iii) the date, if any, fixed as to when the holders of record
of Common Stock are expected to be entitled to exchange their Common Stock for securities or other property deliverable upon such reorganization,
reclassification, transfer, consolation, merger, dissolution, liquidation or winding up.

 

    8

     

    

 

18. RESERVATION
OF SHARES

 

Prior to the expiration of the
Exercise Period, the Company shall reserve and keep available out of its authorized but unissued capital stock for issuance upon the exercise
of this Warrant, free from pre-emptive rights, such number of Warrant Shares for which this Warrant shall from time to time be exercisable.
The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein
without violation of any applicable law or regulation. Without limiting the generality of the foregoing, the Company covenants that it
will take all such legal action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid
and nonassessable Warrant Shares upon the exercise of this Warrant and obtain all such authorizations, exemptions or consents, including
but not limited to consents from the Company’s stockholders or Board of Directors or any public regulatory body, as may be necessary
to enable the Company to perform its obligations under this Warrant.

 

19. NO
THIRD PARTY RIGHTS

 

This Warrant is not intended,
and will not be construed, to create any rights in any parties other than the Company and the Holder, and no Person or entity may assert
any rights as third- party beneficiary hereunder.

 

20. AMENDMENT
PROVISION

 

This Warrant and any term hereof
may be changed, waived, discharged or terminated only by an instrument referring to this Warrant and to this Section 20 in particular
and signed by the party against which enforcement of said change, waiver, discharge or termination is sought.

 

[SIGNATURE PAGE FOLLOWS]

 

    9

     

    

 

IN WITNESS WHEREOF,
the Company has caused this Warrant to be duly executed as of the Issuance Date first set forth above.

 

		VARIANT PHARMACEUTICALS, INC.
	 	 	 
	 	By: 	                            
	 	Name: 	 
	 	Title:	 

 

    

     

    

 

EXHIBIT A

NOTICE OF EXERCISE

 

(To be executed by the Holder
of Warrant if such Holder desires to exercise Warrant)

 

To Variant Pharmaceuticals,
Inc.:

 

The undersigned hereby
irrevocably elects to exercise this Warrant and to purchase thereunder, ___________ Warrant Shares issuable upon exercise of the Warrant
and:

 

(i) delivery of $____________
(in cash, certified check, bank draft or money order, as provided for in the foregoing Warrant) and any applicable taxes payable by the
undersigned pursuant to such Warrant; or

 

(ii) surrender of shares in
connection with a Net Issue Exercise (as set forth in the foregoing Warrant) and any applicable taxes payable by the undersigned pursuant
to such Warrant.

 

The undersigned requests that
certificates for such shares be issued in the name of:

 

	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	(Please print name, address and social security or federal employer identification number (if applicable))	 

 

If the shares issuable upon
this exercise of the Warrant are not all of the Warrant Shares which the Holder is entitled to acquire upon the exercise of the Warrant,
the undersigned requests that a new Warrant evidencing the rights not so exercised be issued, dated as of the Issuance Date, in the name
of and delivered to:

 

	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	(Please print name, address and social security or federal employer identification number (if applicable))	 

 

The undersigned hereby represents and warrants
that (i) the undersigned meets the requirements of at least one of the suitability standards for an “accredited investor”
as that term is defined in Regulation D as promulgated by the United States Securities and Exchange Commission; (ii) the undersigned is
acquiring the Warrant Shares solely for the undersigned’s account for investment purposes only and not with a view to or intent
of resale or distribution thereof, in whole or in part, in violation of the Securities Act of 1933, as amended (the “Act”),
and the undersigned has no present intention of selling, granting any participation in, or otherwise distributing the same in violation
of the Act, without prejudice, however, to the undersigned’s right at all times to sell or otherwise dispose of all or any part
of the Warrant Shares in compliance with applicable federal and state securities laws and in compliance with any transfer restriction
to which the applicable Warrant Shares may be subject at any time or from time to time; and (iii) the undersigned has such knowledge and
experience in financial, tax, and business matters, and, in particular, investments in securities, so as to enable it to utilize the information
made available to it in connection with the License Agreement and the Subscription Agreement to evaluate the merits and risks of an investment
in the Company and the Warrant Shares and to make an informed investment decision with respect thereto.

 

	 	Name of Holder (print):___________________________________
	 	 
	 	(Signature):  ___________________________________________
	 	 
	 	(By:)_________________________________________________
	 	 
	 	(Title:) _______________________________________________
	 	 
	 	Dated:  _______________________________________________

 

    

     

    

 

EXHIBIT B

 

FORM OF ASSIGNMENT

 

FOR VALUE RECEIVED, ____________________
hereby sells, assigns and transfers to each assignee set forth below all of the rights of the undersigned under the Warrant (as defined
in and evidenced by the attached Warrant) to acquire the number of Warrant Shares set opposite the name of such assignee below and in
and to the foregoing Warrant with respect to said acquisition rights and the shares issuable upon exercise of the Warrant:

 

	
     

    Name of Assignee
	Address	Number of Shares
	 	 	 
	 	 	 
	 	 	 
	 	 	 

 

If the total of the Warrant
Shares are not all of the Warrant Shares evidenced by the foregoing Warrant, the undersigned requests that a new Warrant dated as of the
Issuance Date and evidencing the right to acquire the Warrant Shares not so assigned be issued in the name of and delivered to the undersigned.

 

	 	Name of Holder (print):___________________________________
	 	 
	 	(Signature):  ___________________________________________
	 	 
	 	(By:)_________________________________________________
	 	 
	 	(Title:) _______________________________________________
	 	 
	 	Dated:  _______________________________________________Exhibit 10.6.1

 

INCENTIVE STOCK OPTION GRANT AGREEMENT

ZYVERSA THERAPEUTICS, INC.

 

This Stock Option Grant Agreement
(the “Grant Agreement”) is made and entered into effective on the Date of Grant set forth in Exhibit A (the
“Date of Grant”) by and between Zyversa Therapeutics, Inc., a Delaware corporation (the “Company”),
and the individual named in Exhibit A hereto (the “Optionee”).

 

WHEREAS, the Company desires
to provide the Optionee an incentive to participate in the success and growth of the Company through the opportunity to earn a proprietary
interest in the Company; and

 

WHEREAS, to give effect to
the foregoing intention, the Company desires to grant the Optionee an option pursuant to the Zyversa Therapeutics, Inc. 2022 Omnibus Equity
Incentive Plan (the “Plan”) to acquire the Company’s common stock, par value $0.0001 per share (the “Common
Stock”);

 

NOW, THEREFORE, in consideration
of the mutual covenants hereinafter set forth and for good and valuable consideration, the parties hereto agree as follows:

 

1.   Grant.
The Company hereby grants the Optionee an Incentive Stock Option (the “Option”) to purchase up to the number of shares
of Common Stock (the “Shares”) set forth in Exhibit A hereto at the exercise price per Share (the “Exercise
Price”) set forth in Exhibit A, and on the vesting schedule set forth in Exhibit A, subject to the terms and conditions
set forth herein and the provisions of the Plan, the terms of which are incorporated herein by reference. Capitalized terms used but not
otherwise defined in this Grant Agreement shall have the meanings as set forth in the Plan.

 

This Option is intended to
qualify as an Incentive Stock Option (“ISO”) under Section 422 of the Code. However, notwithstanding such designation, if
the Optionee becomes eligible in any given year to exercise ISOs for Shares having a Fair Market Value in excess of $100,000, those options
representing the excess shall be treated as Non-Qualified Stock Options. In the previous sentence, “ISOs” include ISOs granted
under any plan of the Company or any parent or any Subsidiary of the Company. For the purpose of deciding which options apply to Shares
that “exceed” the $100,000 limit, ISOs shall be taken into account in the same order as granted. The Fair Market Value of
the Shares shall be determined as of the time the Option with respect to such Shares is granted. The Optionee hereby acknowledges that
there is no assurance that the Option will, in fact, be treated as an Incentive Stock Option under Section 422 of the Code.

 

2.   Exercise
Period Following Termination of Continuous Service. This Option shall terminate and be canceled to the extent not exercised within
ninety (90) days after the Optionee’s Continuous Service terminates, except that if such termination is due to the death or Disability
of the Optionee, this Option shall terminate and be canceled one (1) year from the date of termination of Continuous Service. Notwithstanding
the foregoing, in the event that the Optionee’s Continuous Service is terminated for Cause, then the Option shall immediately terminate
on the date of such termination of Continuous Service and shall not be exercisable for any period following such date. In no event, however,
shall this Option be exercised later than the Expiration Date set forth in Exhibit A and in no event shall this Option be exercised
for more Shares than the Shares which otherwise have become exercisable as of the date of termination.

 

     

     

    

 

3.   Method
of Exercise. This Option is exercisable by delivery to the Company of an exercise notice (the “Exercise Notice”)
in a form satisfactory to the Committee or by such other form or means as the Committee may permit or require. A sample Exercise Notice
is attached as Exhibit B. The Committee may, however, require Optionee to submit a different form of Exercise Notice. Any Exercise
Notice shall state or provide the number of Shares with respect to which the Option is being exercised (the “Exercised Shares”),
and include such other representations and agreements as may be required by the Company pursuant to the provisions of the Plan. The Exercise
Notice shall be accompanied by payment of the aggregate Exercise Price for the Exercised Shares in (i) cash; (ii) check; or (iii) such
other manner as is acceptable to the Committee, provided that such form of consideration is permitted by the Plan and by applicable law.
Upon exercise of the Option by the Optionee and prior to the delivery of such Exercised Shares, the Company shall have the right to require
the Optionee to satisfy applicable Federal and state tax income tax withholding requirements and the Optionee’s share of applicable
employment withholding taxes in a method satisfactory to the Company. Notwithstanding the foregoing, no Exercised Shares shall be issued
unless such exercise and issuance complies with the requirements relating to the administration of stock option plans and other applicable
equity plans under U.S. state corporate laws, U.S. federal and state securities laws, the Code, any stock exchange or quotation system
on which the Common Stock is listed or quoted, and the applicable laws of any foreign country or jurisdiction where stock grants or other
applicable equity grants are made under the Plan; assuming such compliance, for income tax purposes the Exercised Shares shall be considered
transferred to the Optionee on the date the Option is exercised with respect to such Shares.

 

4.   Covenants
Agreement. This Option shall be subject to forfeiture at the election of the Company in the event that the Optionee breaches any agreement
between the Optionee and the Company with respect to noncompetition, nonsolicitation, assignment of inventions and contributions and/or
nondisclosure obligations of the Optionee.

 

5.   Taxes.
By executing this Grant Agreement, Optionee acknowledges and agrees that Optionee is solely responsible for the satisfaction of any applicable
taxes that may be imposed on Optionee that arise as a result of the grant, vesting or exercise of the Option, including without limitation
any taxes arising under Section 409A of the Code (regarding deferred compensation) or Section 4999 of the Code (regarding golden parachute
excise taxes), and that neither the Company nor the Committee shall have any obligation whatsoever to pay such taxes or otherwise indemnify
or hold Optionee harmless from any or all of such taxes.

 

6.   Non-Transferability
of Option. This Option may not be transferred in any manner otherwise than by will or by the laws of descent or distribution and may
be exercised during the lifetime of the Optionee only by the Optionee. The terms of the Plan and this Grant Agreement shall be binding
upon the executors, administrators, heirs, successors and assigns of the Optionee.

 

    -2-

     

    

 

7.   Securities
Matters. All Shares and Exercised Shares shall be subject to the restrictions on sale, encumbrance and other disposition provided
by Federal or state law. The Company shall not be obligated to sell or issue any Shares or Exercised Shares pursuant to this Grant Agreement
unless, on the date of sale and issuance thereof, such Shares are either registered under the Securities Act of 1933, as amended (the
“Securities Act”), and all applicable state securities laws, or are exempt from registration thereunder. Regardless
of whether the offering and sale of Shares under the Plan have been registered under the Securities Act, or have been registered or qualified
under the securities laws of any state, the Company at its discretion may impose restrictions upon the sale, pledge or other transfer
of such Shares (including the placement of appropriate legends on stock certificates or the imposition of stop-transfer instructions)
if, in the judgment of the Company, such restrictions are necessary in order to achieve compliance with the Securities Act or the securities
laws of any state or any other law.

 

8.   Investment
Purpose. The Optionee represents and warrants that unless the Shares are registered under the Securities Act, any and all Shares acquired
by the Optionee under this Grant Agreement will be acquired for investment for the Optionee’s own account and not with a view to,
for resale in connection with, or with an intent of participating directly or indirectly in, any distribution of such Shares within the
meaning of the Securities Act. The Optionee agrees not to sell, transfer or otherwise dispose of such Shares unless they are either (1)
registered under the Securties Act and all applicable state securities laws, or (2) exempt from such registration in the opinion of Company
counsel.

 

9.   Lock-Up
Agreement. The Optionee hereby agrees that in the event that the Optionee exercises this Option during a period in which any directors
or officers of the Company have agreed with one or more underwriters not to sell securities of the Company, then, as a condition to such
exercise, the Optionee shall enter into an agreement, in form and substance satisfactory to the Company, pursuant to which the Optionee
shall agree to restrictions on transferability of the Shares comparable to the restrictions agreed upon by such directors or officers
of the Company.

 

10.   Other
Plans. No amounts of income received by the Optionee pursuant to this Grant Agreement shall be considered compensation for purposes
of any pension or retirement plan, insurance plan or any other employee benefit plan of the Company or its subsidiaries, unless otherwise
expressly provided in such plan.

 

11.   No
Guarantee of Continued Service. The Optionee acknowledges and agrees that the right to exercise the Option pursuant to the exercise
schedule hereof is earned only through Continuous Service and such other requirements, if any, as are set forth in Exhibit A (and not
through the act of being hired, being granted an option or purchasing shares hereunder). The Optionee further acknowledges and agrees
that (i) this Grant Agreement, the transactions contemplated hereunder and the exercise schedule set forth herein do not constitute an
express or implied promise of continued employment or service for the exercise period or for any other period, and shall not interfere
with the Optionee’s right or the right of the Company or its Subsidiaries to terminate the employment or service relationship at
any time, with or without cause, subject to the terms of any written employment agreement that the Optionee may have entered into with
the Company or any of its Subsidiaries; and (ii) the Company would not have granted this Option to the Optionee but for these acknowledgements
and agreements.

 

    -3-

     

    

 

12.   Entire
Agreement; Governing Law. The Plan is incorporated herein by reference. The Plan and this Grant Agreement constitute the entire agreement
of the parties with respect to the subject matter hereof and supersede in their entirety all prior undertakings and agreements of the
Company and the Optionee with respect to the subject matter hereof, and may not be modified adversely to the Optionee’s interest
except by means of a writing signed by the Company and the Optionee. In the event of any conflict between this Grant Agreement and the
Plan, the Plan shall be controlling, except as otherwise specifically provided in the Plan. This Grant Agreement shall be construed under
the laws of the State of Delaware, without regard to conflict of laws principles.

 

13.   Opportunity
for Review. Optionee and the Company agree that this Option is granted under and governed by the terms and conditions of the Plan
and this Grant Agreement. The Optionee has reviewed the Plan and this Grant Agreement in their entirety, has had an opportunity to obtain
the advice of counsel prior to executing this Grant Agreement and fully understands all provisions of the Plan and this Grant Agreement.
The Optionee hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Committee upon any questions
relating to the Plan and this Grant Agreement. The Optionee further agrees to notify the Company upon any change in the residence address
indicated herein.

 

14.Section 409A.This
Option is intended to be excepted from coverage under Section 409A and shall be administered, interpreted and construed accordingly. The
Company may, in its sole discretion and without the Optionee’s consent, modify or amend the terms of this Grant Agreement, impose
conditions on the timing and effectiveness of the exercise of the Option by Optionee, or take any other action it deems necessary or advisable,
to cause the Option to be excepted from Section 409A (or to comply therewith to the extent the Company determines it is not excepted).

 

15.   Recoupment.
In the event the Company restates its financial statements due to material noncompliance with any financial reporting requirements under
applicable securities laws, any shares issued pursuant to this Agreement for or in respect of the year that is restated, or the prior
three years, may be recovered to the extent the shares issued exceed the number that would have been issued based on the restatement.
In addition and without limitation of the foregoing, any amounts paid hereunder shall be subject to recoupment in accordance with The
Dodd–Frank Wall Street Reform and Consumer Protection Act and any implementing regulations thereunder, any clawback policy adopted
by the Company or as is otherwise required by applicable law or stock exchange listing conditions.

 

[Signature Page Follows]

 

    -4-

     

    

 

IN WITNESS WHEREOF, the parties hereto have executed
this Grant Agreement as of the date set forth in Exhibit A.

 

	 	ZYVERSA THERAPEUTICS, INC.
	 	 
	 	By:	                
	 	 	Name:
	 	 	Title:
	 	 
	 	OPTIONEE 
	 	
	 	 
	 	Name:

 

    -5-

     

    

 

EXHIBIT
A

 

INCENTIVE STOCK OPTION GRANT AGREEMENT

 

ZYVERSA THERAPEUTICS, INC.

 

(a). Optionee’s
Name: ________________________________

 

(b). Date of Grant: _____________________

 

(c). Number of Shares Subject to the
Option:  ______________

 

(d).   Exercise
Price: $______ per Share

 

(e). Expiration Date: ___________________

 

(f). Vesting
Schedule: The Option shall vest as to [twenty-five percent (25%)] of the Shares subject thereto on the one-year anniversary of
the Date of Grant (the “First Vesting Date”) and as to the remaining [seventy-five percent (75%)] of the Shares subject
thereto ratably over the next [thirty-six (36)] months thereafter beginning on the first monthly anniversary of the First Vesting
Date and continuing on each monthly anniversary of the First Vesting Date thereafter; provided that Optionee is in Continuous
Service on each such respective vesting date.

 

_______ (Initials)

 Optionee

 

_______ (Initials)

Company Signatory

 

    -6-

     

    

 

EXHIBIT
b

 

ZYVERSA THERAPEUTICS, INC.

2022 OMNIBUS EQUITY INCENTIVE PLAN

 

STOCK OPTION EXERCISE NOTICE

 

Zyversa Therapeutics, Inc.

2200 N Commerce Pkwy STE 208

Weston, FL 33326

Attention: Chief Financial Officer

 

1. Exercise of Option. Effective as of
today, ________________, 202__ (the “Exercise Date”), the undersigned (“Purchaser”) hereby elects to purchase ________
shares (the “Shares”) of the Common Stock of Zyversa Therapeutics, Inc. (the “Company”) under and pursuant to
the Stock Option Grant Agreement dated _____________, 202_ (the “Option Agreement”). Pursuant to the Option Agreement, the
aggregate purchase price for the Shares is $_____________ (the “Purchase Price”). Capitalized terms used herein and not otherwise
defined shall have the meaning assigned thereto under the Zyversa Therapeutics, Inc. 2022 Omnibus Equity Incentive Plan (the “Plan”).

 

2. With respect to payment of the Purchase Price,
select A or B as follows:

 

A. [   ] Full Payment. Purchaser herewith
makes payment of a check the full Purchase Price to the Company, either:

 

[   ] by enclosing a check payable
to Zyversa Therapeutics, Inc., or

 

[   ] by transfer of funds by
wire transfer to the Company.

 

B. [   ] Cashless Exercise. Purchaser elects
to exercise via “cashless exercise” through a broker approved by the Company, and agrees to execute and deliver all appropriate
forms as may be required by such broker and/or the Company. I hereby authorize the broker will pay to the Company the Purchase Price plus
an amount sufficient to cover all applicable taxes, as determined by the Company.

 

3. Rights as Shareholder. Until the issuance
(as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company) of the Shares,
no right to vote or receive dividends or any other rights as a shareholder shall exist with respect to the Shares covered by the Option,
notwithstanding the exercise of the Option. The Shares so acquired shall be issued to the Optionee as soon as practicable after exercise
of the Option. No adjustment will be made for a dividend or other right for which the record date is prior to the date of issuance.

 

    -7-

     

    

 

4. Tax Consultation. Purchaser understands
that Purchaser may suffer adverse tax consequences as a result of Purchaser’s purchase or disposition of the Shares. Purchaser represents
that Purchaser has consulted with any tax consultants Purchaser deems advisable in connection with the purchase or disposition of the
Shares and that Purchaser is not relying on the Company for any tax advice.

 

5. Entire Agreement; Governing Law. The
Option Agreement is incorporated herein by reference. This Agreement and the Option Agreement constitute the entire agreement of the parties
with respect to the subject matter hereof and supersede in their entirety all prior undertakings and agreements of the Company and the
Purchaser with respect to the subject matter hereof, and may not be modified adversely to the Purchaser’s interest except by means of
a writing signed by the Company and Purchaser. This agreement is governed by the internal substantive laws, but not the choice of law
rules, of the State of Delaware.

 

	Submitted by: 	 	Accepted by:
	 	 	 
	PURCHASER	 	ZYVERSA THERAPEUTICS, INC.
	 	 	 
			By:	                  
	 	 	 
		 	 
	Print Name 	 	Print Name/Title
	 	 	 
	Date:	             		Date:	 

 

    -8-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00348-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00348-of-00352.parquet"}]]